12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

PHASE3CompletedINTERVENTIONAL
Enrollment

535

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
DRUG

Ibodutant 10 mg

Oral tablet, to be given once daily.

DRUG

Placebo

Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.

Trial Locations (127)

1407

Sofia

1431

Sofia

4002

Plovdiv

5000

Veliko Tarnovo

6300

Haskovo

7002

Rousse

8304

Mataró

10530

Hartsdale

10629

Berlin

13125

Berlin

14021

Prague

19000

Prague

19606

Reading

20125

Bucharest

20253

Hamburg

21215

Baltimore

22297

Hamburg

26505

Morgantown

27100

Pavia

27408

Greensboro

28040

Madrid

28304

Fayetteville

29650

Greer

29681

Simpsonville

31009

Krakow

32607

Gainesville

33000

Bordeaux

33012

Hialeah

33014

Miami Lakes

33125

Miami

33134

Coral Gables

33165

Miami

33175

Miami

33185

Miami

33426

Boynton Beach

33458

Jupiter

33511

Brandon

34601

Brooksville

35802

Huntsville

37167

Smyrna

37205

Nashville

37421

Chattanooga

37912

Knoxville

37919

Knoxville

40138

Bologna

40509

Lexington

41013

Seville

42303

Owensboro

42431

Madisonville

43214

Columbus

44093

Nantes

44122

Cleveland

44302

Akron

45219

Cincinnati

45242

Cincinnati

45355

Essen

45432

Dayton

48047

Chesterfield

48098

Troy

48106

Ann Arbor

48604

Saginaw

50098

Bucharest

50139

Florence

53333

Wroclaw

58103

Fargo

60101

Addison

60604

Chicago

67010

Augusta

67114

Newton

67205

Wichita

70100

Bari

70124

Bari

70526

Crowley

70593

Stuttgart

72120

Sherwood

72205

Little Rock

76031

Rouen

76054

Hurst

77052

Houston

77089

Houston

77530

Ste. Channelview

77701

Beaumont

78229

San Antonio

80127

Littleton

84088

West Jordan

89128

Las Vegas

90701

Artesia

91345

Mission Hills

91436

Encino

91786

Upland

91910

Chula Vista

92123

San Diego

93000

Bobigny

95821

Sacramento

115446

Moscow

150000

Yaroslavl

193015

Saint Petersburg

194295

Saint Petersburg

196247

Saint Petersburg

214019

Smolensk

248007

Kaluga

300168

Timișoara

300193

Timișoara

500283

Brasov

500326

Brasov

540098

Târgu Mureş

540461

Târgu Mureş

06010

Bristol

360 66

Karlovy Vary

401 13

Ústí nad Labem

562 01

Ústí nad Orlicí

06202

Nice

00168

Rome

85-168

Bydgoszcz

42-200

Częstochowa

20-090

Lublin

08916

Badalona

08208

Sabadell

08022

Barcelona

08035

Barcelona

TR18 4JH

Penzance

S40 4AA

Chesterfield

IV2 4AG

Inverness

DN2 5LT

Doncaster

LE10 2SE

Leicestershire

M23 9LT

Manchester

PL5 3JB

Plymouth, Devon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Menarini Group

INDUSTRY

NCT02107196 - 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Biotech Hunter | Biotech Hunter